Skip to main content
SpringerLink
Log in

The US FDA has issued an early communication about its ongoing safety review of abacavir [Ziagen] and didanosine [Videx]

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. FDA.Early Communication about an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine). Media Release: 27 Mar 2008. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The US FDA has issued an early communication about its ongoing safety review of abacavir [Ziagen] and didanosine [Videx]. React. Wkly. 1196, 4 (2008). https://doi.org/10.2165/00128415-200811960-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811960-00012

Keywords

Search

Navigation